Previous 10 | Next 10 |
CV Sciences (OTCQB:CVSI +11.0%) has entered into a securities purchase agreement with an institutional investor, providing for the sale and issuance of convertible notes due 2022 in principal amount of $1.06M. The Co. may elect to offer and sell up to and additional $4.24M in aggregate princi...
CV Sciences, Inc. (CVSI) Q3 2021 Earnings Conference Call November 15, 2021 10:00 AM ET Company Participants Unidentified Company Representative – Unidentified Joseph Dowling – Chief Executive Officer Joerg Grasser – Chief Financial Officer Conference Call Participants Sc...
Palm Beach, FL – November 15, 2021 – FinancialNewsMedia.com News Commentary – Out of all cannabinoids, cannabidiol is most widely used for therapeutic reasons due to the lack of psychoactive effects. In many medical applications, cannabidiol oil is used, suc...
CV Sciences, Inc. (OTCQB:CVSI) announced its financial results for the quarter ended September 30, 2021, with revenue falling 8% to $5.1 million for the third quarter of 2021 versus $5.6 million for the third quarter of 2020. CV Sciences said that sales were hurt by increased ...
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced t...
CV Sciences (OTCQB:CVSI): Q3 GAAP EPS of $0.00 beats by $0.03. Revenue of $5.11M (-8.1% Y/Y) misses by $0.47M. Gross margin of 46.2% for Q3, improved from 44.2% for Q3 2020. “Third quarter results met our expectations and we are very encouraged by recent legislative actions including t...
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced i...
ACM, ACRX, ADN, AMPY, AVPT, AYRO, BCLI, BFLY, CLSN, OTCQB:CVSI, FREY, GMDA, GOED, KALA, MICT, OEG, ONDS, OTLY, PLX, PTN, RAIL, SOHU, TLS, TRVN, TSN, VBLT For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today ann...
SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, applauds the Cali...
News, Short Squeeze, Breakout and More Instantly...
CV Sciences, Inc. Reports First Quarter 2024 Financial Results PR Newswire SAN DIEGO , May 14, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER PR Newswire SAN DIEGO , May 13, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer we...
CV Sciences, Inc. To Announce First Quarter 2024 Results On May 14, 2024 PR Newswire SAN DIEGO , May 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company special...